All Asia Licensing Inc. (Pink Sheets: AASI), today announced that it
accepted an invitation for its chief scientist to lead a workshop
September 23-25 in China at a major international conference on
little-known animal diseases.
“This prestigious invitation from an arm of
China’s Ministry of Agriculture is a direct
result of our recently-announced Letter of Intent to enter the bio
research market to test for BSE (Bovine Spongiform Encephalopathy) also
known as ‘Mad Cow’
Disease,” according to Anthony Lee, CEO of All
Asia Licensing.
The National Diagnostic Center for Exotic Animal Disease of China is the
main sponsor of the Third OIE (Office International des Epizooties
Regional Workshop and Working Group Meeting on BSE and other Prion
Diseases. The conference is also co-sponsored in Qingdao, People’s
Republic of China by its Animal Health and Epidemiology Center (CAHEC).
The main topics at the conference will be the control of Mad Cow
Disease, Rapid Prion Testing and Prion disease diagnosis. Prions are a
family of rare progressive neurodegenerative disorders.
The Letter of Intent announced between All Asia and its proposed joint
venture partner is subject to change, completion of due diligence by
both parties, creation of a final contract and approval of both Boards
of Directors, among other things.
All Asia Licensing Inc. is a major conduit for investors to access the
rapidly growing Chinese economy. By acquiring a controlling stake in
unique Chinese businesses, using its contacts to work with governmental
agencies, providing capital and international-minded management, the
Company enables these companies to prosper in their own industries.
Working with small-to-medium sized companies, All Asia assists clients
by using a comprehensive suite of services of business management,
consulting services and technical support through specialist networks.
“Safe Harbor Statement”
Under the Private Securities Litigation Reform Act of 1995:
Certain statements in this news release are “forward-looking
statements” within the meaning of the Private
Securities Litigation Act of 1995. These statements include, without
limitation, statements concerning the ultimate signing of a definitive
contract, its impact on our future business prospects and our ability to
successfully complete the commercialization of the bio research testing
and grading system in China. These forward-looking statements are based
on our current expectations and beliefs and are subject to a number of
risk factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. Such
risks and uncertainties include the risks that the Letter of Intent will
not lead to a successful acquisition of 50% interest in the proposed
joint venture; the results we intend are not achieved; and the risks
inherent in commercializing a new testing and grading system (including
technology risks, market risks, financial risks and implementation
risks, as well as other risks and uncertainties affecting the Company)
inhibit market penetration. These risks are to be included in filings
with the Securities and Exchange Commission, all of which are to be
available at www.sec.gov. We disclaim
any intention or obligation to revise any forward-looking statements,
including, without limitation, financial estimates, whether as a result
of new information, future events or otherwise.
Greg McAndrews & Associates
Gregory A. McAndrews,
310-301-3035
Fax: 310-827-7416
greg@gregmcandrews.com
or
All
Asia Licensing Inc.
Investor Relations, +1-866-575-6854
Fax:
+1-877-420-7950
ir@allasialicensing.com
